Showing posts with label rucaparib. Show all posts
Showing posts with label rucaparib. Show all posts

Thursday, June 8, 2023

ASCO23 Day 3 :Parp Inhibitors & Late Breaking Abstract session

While there were fewer gynecologic cancer sessions on Day 3, Sunday June 4th there were two important sessions regarding the use of PARP inhibitors and trial results for a drug to teat  platinum resistant ovarian cancer drug which may be change practice.

Parp Inhibitor Optimal Selection and Toxicity Management 

Dr Tew - Status updates on Parp use


Dr Friedlander- Real World Experience in Managing PARP Toxicities 


 


 


 Susan Feinberg  (FORCE) - Living on a PARPi 


 


Late Breaking Abstract Session  
Mirvetixumab in Folate Receptor Alpha positive platinum resistant ovarian cancer

I wish I had been able to be in the room when this session took place. I could feel the excitement from the Tweets being posted.  This is the first trial to show overall survival benefit in platinum resistant ovarian cancer! This is practice changing. 

 Here is a slide of the overall survival  MIRV 16.46 months vs investigator choice of treatment 12.75 months.


 Stop by tomorrow for highlights from my last day of ASCO - Day 4 . 


Dee

Every Day is a Blessing

Posted by at No comments:
Labels: , , , , , , ,

Thursday, June 9, 2022

News from #ASCO22 - Part 2, Gyn Cancer Oral Abstract Session

 The #ASCO22 Oral Abstract session for Gynecologic Cancers was held on June 6, 2022. 

ATHENA–MONO (GOG-3020/ENGOT-ov45) trial - Improved Progression Free Survival, OC

Ruxolitinib  in OC

Bevacizumab  use in ovarian cancer clear cell carcinoma, Japanese study

Discussion of prior 3 OC studies 

Relacorilant in recurrent OC ,  <2 month PFS as well as OS

 Trabectedin in OC, Fallopian tube cancer - No improvement in OS survival , OC

PESCO trial P1 expansion trial Pembro,  maveropepimut-S & cyclophosphamide, OC

Discussion of prior 3 studies 

Keynote 826  Cervical cancer

ENGOT Cx8/GOG 3024/innovaTV 205 Cervical Cancer 

Covid 19 in Gyn cancer patients 

Thank you Dr Shannon Westin for tweeting from the session. 

Next up  Addressing Challenges in Ovarian Cancer Management. 

Dee
Every Day is a Blessing!
Posted by at No comments:
Labels: , , , , , , ,

Wednesday, June 8, 2022

News from ASCO 2022 - Part 1 Gyn Cancer/ Survivorship Posters

The last post I wrote I was very excited to be going to Chicago to attend #ASCO22 Annual meeting. I had to change those plans after I started experiencing vertigo. My PCP advised me to not fly. So I cancelled my hotel and flight and switched gears to attend the meeting virtually.  

The set up for the virtual meeting this year allowed some sessions to be viewed live and other sessions would be available to watch On Demand later for those virtual attendees. The tech was not cooperating with me on Friday, most of Saturday until late on Sunday. I appreciate all the time that ASCO staff and IT spend with me trying to resolve my issue. In the future I will not use " in my name. 

Because of that delay, I will report on the posters which I could access first and then the other sessions. 

POSTERS  Gyn Cancer Research 

Interesting process for dispersing chemotherapy in the abdomen of women with OC

How sensitive is rucaparib in women with OC who do not have homologous recombination deficiency

Next Generation Sequencing in OC

BRAF, PIK3R1, NOTCH3,MET, and/or ATR correlated with shorter PFS 
ATM, RB1, CDKN2A, FGFR1, and/or FGFR2 associated with improved PFS 

Clear Cell Genomic Analysis

KELIM  - Algorithm that is calculated with 6 to 7 CA-125 values measured during the first 100 days after chemotherapy start

Suggests that bevicizumab is mainly effective in patients w/ poorly chemosensitive diseases. Highest benefit from bevacizumab in PFS and OS were high-risk diseases (stage IV, or incompletely.

Possible  biomarker test for OC uses extracellular vesicles

Posters Survivorship

 1 Frailty, 2 Cooling Caps, 3 Yoga, 4 Acupuncture for Neuropathy

 

 

 Stay tuned over the next few days for additional information on gyn cancer specific sessions. 

Dee

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , , , , ,

Tuesday, March 27, 2018

#SGOmtg Twitter Highlights - Research Highlights Sunday March 25, 2018

Sunday was another busy day of information sharing at the SGO Annual Meeting in New Orleans.
Here are the topics that caught my eye while following the #SGOmtg hashtag.

Ovarian Cancer Maintenance Rucaparib - NOVA Study
Ovarian Cancer - Niraparib and Cost effectiveness
Ovarian Cancer - Parp inhibitor and BRCA status



Endometrial Cancer GOG 86 P Predictive biomarkers of endometrial cancer

Endometrial Cancer PORTEC3

Endometrial - GOG 249

Cervical Cancer - chemo /radiation


Thank you to Rick Boulay,MD, Jolyn Taylor, Don S Dizon, Douglas Levine MD,  Shannon Westin and Deanna Teoh, M.D. for tweeting using the #SGOmtg hashtag so those of us following from a distance can learn.


Dee
Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , , , ,

Monday, March 13, 2017

SGO Meeting Highlights via Twitter ~ Day Two, March 13, 2017

More news from the The Society of Gynecologic Oncology (@SGO_org) Annual Meeting. I am at home and have been following Tweets from the meeting using the hashtag #SGOmtg.

Here are some tweets I found of interest today-  Monday, March 13th.

Endometrial Cancer:



Burnout in Gynecologic  Oncologists


Patient Centered Assessment Tool - Great work done by my friend and fellow advocate Annie Ellis.



IP Chemotherapy


Circulating DNA

 Niraparib
 Rucaparib

Genetic Testing

 GPI -  Glucose-6-phosphate isomerase

Neoadjuvant Chemotherapy


Slides from a Sunday presentation on  PARP

Thanks for all those tweeting from the meeting especially these folks

Looking forward to Tweets from tomorrow's meeting.

Dee Every Day is a Blessing!
Posted by at No comments:
Labels: , , , , , , , ,

Thursday, December 22, 2016

Last Research News of 2016 - Rubraca and FoundationFocus™ CDxBRCA

Another FDA approval for an ovarian cancer treatment happened this week.

"Rubraca is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test." - FDA (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533873.htm)

Rubraca (rucaparib) is a PARP (poly ADP-ribose polymerase)  inhibitor made by Clovis Oncology. The approval is based on two trials. One of the trials is the ARIEL2 trial. In that trial the duration of response was 11.6 months. 

Along with Rubraca, the FDA also approved the  FoundationFocus™ CDxBRCA companion diagnostic to identify those women diagnosed with ovarian cancer who have a BRCA mutation.  This is the first next-generation-sequencing (NGS)-based companion diagnostic approved by the FDA. The test by Foundation Medicine, Inc.  can test for both germline and somatic BRCA mutations in tumor tissue. Germline are inherited mutations and somatic are acquired mutations. 
 
Sources :



Dee
Every Day is a Blessing! 
Posted by at No comments:
Labels: , , , , , ,

Saturday, November 22, 2014

OC News : Bevacizumab, Rucaparib, Trebananib

During the past few weeks there have been a number of developments in Ovarian Cancer  treatment and research in the news. Below are my top three picks.

Bevacizumab (Avastin) for Recurrent Ovarian Cancer

The FDA approved Avastin, a VEGF inhibitor made by Genentech, for treatment of persistent, recurrent or late stage Ovarian Cancer. Avastin can be used with paclitaxel, pegylated liposomal doxorubicin or topotecan chemotherapy.
FDA announce may be found here. 
Genentech Press Release and results of the Phase III AURELIA study can be found here.

6th EORTC-NCI-AACR  Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain News

Researchers identified a biomarker that can predict which women will respond to rucaparib, a PARP inhibitor. Rucaparib is an oral drug. Dr Elizabeth Swisher said "good responses to rucaparib in women with ovarian cancers exhibiting a form of cell damage called genomic loss of heterozygosity (LOH), in which an entire chromosomal region on one copy of the genome is lost" as well as in those who have BRCA1/2 mutations. (http://www.medicalnewstoday.com/releases/285788.php)

Trebananib Fails to Improve Overall Survival 

The trial, TRINOVA-1, tested  Amgen 's drug, trebananib along with Placitaxel. Results show that there was not a significant improvement in overall survival trebananib was used.
Reuter's article - http://www.reuters.com/article/2014/11/04/us-amgen-study-idUSKBN0IO1EW20141104?feedType=RSSfeedName=healthNews


Dee
Every Day is a Blessing !


Posted by at 1 comment:
Labels: , , , , , , , ,
Subscribe to: Posts (Atom)